Cost-effectiveness of nivolumab in squamous and non-squamous non-small cell lung cancer in Canada and Sweden: an update with 5-year data

References

• GLOBOCAN. Global Cancer Observatory 2018 – all cancers fact sheet; 2018. https://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf.
   Google Scholar
• Canadian Cancer Society. Canadian cancer statistics; 2019. http://www.cancer.ca/∼/media/cancer.ca/CW/publications/Canadian%20Cancer%20Statistics/Canadian-Cancer-Statistics-2019-EN.pdf.
   Google Scholar
• International Agency for Research on Cancer. Sweden fact sheets. https://gco.iarc.fr/today/data/factsheets/populations/752-sweden-fact-sheets.pdf.
   Google Scholar
• Canadian Cancer Society. Suvival statistics for non-small cell lung cancer. https://www.cancer.ca/en/cancer-information/cancer-type/lung/prognosis-and-survival/non-small-cell-lung-cancer-survival-statistics/?region=on.
   Google Scholar
• Regionala Cancer Centrum I Samverkan. Lung cancer. https://www.cancercentrum.se/globalassets/cancerdiagnoser/lunga-och-lungsack/kvalitetsregister/rapport/20191015_nlcr_nationell_rapport_2018.pdf.
   Google Scholar
• Nilsson J, Berglund A, Bergstrom S, et al. The role of comorbidity in the management and prognosis in nonsmall cell lung cancer: a population-based study. Acta Oncol. 2017;56(7):949–956.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–135.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Gettinger S, Vokes EE, et al. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2021;39(7):723–733.
   PubMed Web of Science ®Google Scholar
• European Society for Medical Oncology. FDA expands approved use of nivolumab to squamous NSCLC. https://www.esmo.org/oncology-news/FDA-Expands-Approved-Use-of-Nivolumab-to-Squamous-NSCLC.
   Google Scholar
• Oncology Times. FDA approves Opdivo for non-squamous NSCLC. Oncol Times. 2015;37(22):47.
   Google Scholar
• European Medicines Agency. Opdivo. https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo.
   Google Scholar
• Goeree R, Villeneuve J, Goeree J, et al. Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes. J Med Econ. 2016;19(6):630–644.
   PubMed Web of Science ®Google Scholar
• Smare C, Venkatachalam M, Medin E, et al. An economic evaluation of nivolumab for the treatment of squamous and non-squamous NSCLC in the Swedish setting. Nordic J Health Econ. 2019;7(1):47–64.
   Google Scholar
• Rothwell B, Kiff C, Ling C, et al. Cost effectiveness of nivolumab in patients with advanced, previously treated squamous and non-squamous non-small-cell lung cancer in England. Pharmacoecon Open. 2020. DOI:https://doi.org/10.1007/s41669-020-00245-4
   Google Scholar
• Chaudhary A, Lubinga SJ, Smare C, et al. Cost-effectiveness of nivolumab in NSCLC patients in the United States. Am J Manag Care. 2021 (in press).
   Web of Science ®Google Scholar
• OPDIVO (nivolumab) [prescribing information]. Princeton, NJ: Bristol Myers Squibb; 2014.
   Google Scholar
• Nivolumab dosing schedule approved for every 4 weeks. Oncol Times. 2018;40(7):28.
   Google Scholar
• OPDIVO [product monograph]. Montreal, Canada: Bristol Myers Squibb Canada Co.; 2020.
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Guidelines for the Economic Evaluation of Health Technologies: Canada – 4th edition. https://www.cadth.ca/dv/guidelines-economic-evaluation-health-technologies-canada-4th-edition.
   Google Scholar
• Tandvårds- och läkemedelsförmånsverket. Prissökningar i databsen. https://www.tlv.se/beslut/sok-i-databasen.html.
   Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab. JAMA Oncol. 2019;5(10):1411–1420.
   PubMed Web of Science ®Google Scholar
• Barlesi F, Steins M, Horn L, et al., editors. Long-term outcomes with nivolumab vs. docetaxel in patients with advanced NSCLC: CheckMate 017 and CheckMate 057 2-y update. Copenhagen, Denmark: European Society for Medical Oncology 41st Congress; 2016, October 7–11.
   Google Scholar
• Tandvårds- och läkemedelsförmånsverket. Underlag för beslut i landstingen. Opdivo (nivolumab). Koncentrat till infusionsvätska, lösning; 2016. https://www.tlv.se/download/18.467926b615d084471ac3396d/1510316400229/Kunskapsunderlag_opdivo_lungcancer_icke_skivepitel.pdf.
   Google Scholar
• National Institute for Health and Care Excellence. Nivolumab for previously treated squamous non-small-cell lung cancer; 2020. https://www.nice.org.uk/guidance/ta655/chapter/1-Recommendations.
   Google Scholar
• Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33(18):2004–2012.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–1550.
   PubMed Web of Science ®Google Scholar
• Solem CT, Penrod JR, Lees M, et al. Resource utilization among advanced squamous and non-squamous non-small cell lung cancer patients receiving second-line treatment in France, Germany, Italy, and Spain: results of a retrospective medical chart review. Value Health. 2015;18(7):A450.
   Web of Science ®Google Scholar
• Apoteket. Apoteket price database 2019; 2019. https://www.apoteket.se/.
   Google Scholar
• Pan-Canadian Oncology Drug Review. Final economic guidance report: atezolizumab (Tecentriq) for non-small cell lung cancer; 2018. https://www.cadth.ca/sites/default/files/pcodr/pcodr_atezolizumab_tecentriq_nsclc_fn_cgr.pdf.
   Google Scholar
• Pan-Canadian Oncology Drug Review. Final economic guidance report: nivolumab (Opdivo) for non-small cell lung cancer; 2016. https://www.cadth.ca/sites/default/files/pcodr/nivolumab_opdivo_nsclc_fn_egr.pdf.
   Google Scholar
• Pan-Canadian Oncology Drug Review. Final economic guidance report: pembrolizumab (Keytruda) for nonsquamous non-small cell lung cancer; 2019. https://www.cadth.ca/sites/default/files/pcodr/Reviews2019/10153PembroNSQ-NSCLC_fnEGR_NOREDACT-ABBREV_Post_31May2019_final.pdf.
   Google Scholar
• Pan-Canadian Oncology Drug Review. Pan-Canadian oncology drug review initial economic guidance report: osimertinib (Tagrisso) for advanced or metastatic non-small cell lung cancer; 2018. https://cadth.ca/sites/default/files/pcodr/pcodr_osimertinib_tagrisso_nsclc_1stln_in_egr.pdf.
   Google Scholar
• Ontario Ministry of Health. Ontario schedule of benefits. http://www.health.gov.on.ca/en/pro/programs/ohip/sob/.
   Google Scholar
• Södra sjukvårdsregionen. Regionala priser och ersättningar; 2020. https://sodrasjukvardsregionen.se/verksamhet/avtal-priser/.
   Google Scholar
• Walker H, Anderson M, Farahati F, et al. Resource use and costs of end-of-life/palliative care: Ontario adult cancer patients dying during 2002 and 2003. J Palliat Care. 2011;27(2):79–88.
   PubMed Web of Science ®Google Scholar
• Norwegian Medicines Agency (NoMA). Sweden's dental and pharmaceutical benefits agency (TLV). FINOSE joint assessment report: Tecentriq (atezolizumab); 2018. https://www.tlv.se/download/18.799b0a9f16b9029968838c8/1561553375250/bes_190617_tecentriq_eng.pdf.
   Google Scholar
• Wehler E, Zhao Z, Pinar Bilir S, et al. Economic burden of toxicities associated with treating metastatic melanoma in eight countries. Eur J Health Econ. 2017;18(1):49–58.
   PubMed Web of Science ®Google Scholar
• Bansback N, Tsuchiya A, Brazier J, et al. Canadian valuation of EQ-5D health states: preliminary value set and considerations for future valuation studies. PLoS One. 2012;7(2):e31115.
   PubMed Web of Science ®Google Scholar
• Burstrom K, Sun S, Gerdtham UG, et al. Swedish experience-based value sets for EQ-5D health states. Qual Life Res. 2014;23(2):431–442.
   PubMed Web of Science ®Google Scholar
• Lloyd A, van Hanswijck de Jonge P, Doyle S, et al. Health state utility scores for cancer-related anemia through societal and patient valuations. Value Health. 2008;11(7):1178–1185.
   PubMed Web of Science ®Google Scholar
• Nafees B, Stafford M, Gavriel S, et al. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes. 2008;6(1):84.
   PubMed Web of Science ®Google Scholar
• Tolley K, Goad C, Yi Y, et al. Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia. Eur J Health Econ. 2013;14(5):749–759.
   PubMed Web of Science ®Google Scholar
• Chouaid C, Agulnik J, Goker E, et al. Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world setting. J Thorac Oncol. 2013;8(8):997–1003.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Borghaei H, Ramalingam SS, et al. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol. 2019;20(10):1395–1408.
   PubMed Web of Science ®Google Scholar
• Pan-Canadian Oncology Drug Review. pCODR expert review committee (pERC) final recommendation: nab-paclitaxel (Abraxane); 2014. https://www.cadth.ca/sites/default/files/pcodr/pcodr-abraxane-mpc-fn-rec.pdf.
   Google Scholar
• Ontario Ministry of Health. Schedule of benefits for laboratory services; 2020. http://www.health.gov.on.ca/en/pro/programs/ohip/sob/lab/lab_mn2020.pdf.
   Google Scholar